GB202114655D0 - Biomarkers - Google Patents

Biomarkers

Info

Publication number
GB202114655D0
GB202114655D0 GBGB2114655.0A GB202114655A GB202114655D0 GB 202114655 D0 GB202114655 D0 GB 202114655D0 GB 202114655 A GB202114655 A GB 202114655A GB 202114655 D0 GB202114655 D0 GB 202114655D0
Authority
GB
United Kingdom
Prior art keywords
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2114655.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hvivo Services Ltd
Original Assignee
Hvivo Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hvivo Services Ltd filed Critical Hvivo Services Ltd
Priority to GBGB2114655.0A priority Critical patent/GB202114655D0/en
Publication of GB202114655D0 publication Critical patent/GB202114655D0/en
Priority to PCT/GB2022/052610 priority patent/WO2023062378A1/en
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/80ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/11Orthomyxoviridae, e.g. influenza virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/521Chemokines
    • G01N2333/522Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/521Chemokines
    • G01N2333/523Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Primary Health Care (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Databases & Information Systems (AREA)
  • Medicinal Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
GBGB2114655.0A 2021-10-13 2021-10-13 Biomarkers Ceased GB202114655D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2114655.0A GB202114655D0 (en) 2021-10-13 2021-10-13 Biomarkers
PCT/GB2022/052610 WO2023062378A1 (en) 2021-10-13 2022-10-13 Methods of assessing whether a subject is at risk of developing severe symptoms of disease and/or becoming contagious after exposure, or possible exposure, to a respiratory virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2114655.0A GB202114655D0 (en) 2021-10-13 2021-10-13 Biomarkers

Publications (1)

Publication Number Publication Date
GB202114655D0 true GB202114655D0 (en) 2021-11-24

Family

ID=78594996

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2114655.0A Ceased GB202114655D0 (en) 2021-10-13 2021-10-13 Biomarkers

Country Status (2)

Country Link
GB (1) GB202114655D0 (en)
WO (1) WO2023062378A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012004620A (en) * 2009-10-19 2012-06-25 Theranos Inc Integrated health data capture and analysis system.
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
GB201721793D0 (en) 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza

Also Published As

Publication number Publication date
WO2023062378A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
GB201919219D0 (en) Cancer biomarkers
GB201902077D0 (en) Biomarkers
GB202103080D0 (en) Cancer biomarkers
GB201911947D0 (en) Miscarriage biomarkers
GB201908780D0 (en) Melanoma biomarkers
GB201900677D0 (en) Biomarkers
GB202103951D0 (en) Biomarkers
GB202107813D0 (en) Biomarker
SG11202110589PA (en) Biomarkers for selinexor
GB202114655D0 (en) Biomarkers
GB202111201D0 (en) Biomarkers
GB202103140D0 (en) Biomarkers
GB202015056D0 (en) Biomarkers
GB202014190D0 (en) Biomarkers
GB202005435D0 (en) Biomarkers
GB202001361D0 (en) Biomarkers
GB202114656D0 (en) Biomarker
GB202112831D0 (en) Biomarker
GB202110365D0 (en) Biomarker
GB202014824D0 (en) Biomarker
GB202314954D0 (en) Biomarkers
GB202216295D0 (en) Biomarkers
GB202215749D0 (en) Biomarkers
GB202212826D0 (en) Biomarkers
EP4308936A4 (en) Novel biomarker

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)